CpG oligodeoxynucleotides as mucosal adjuvants

References

• McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10:75-88; PMID:1539467; http://dx.doi.org/10.1016/0264-410X(92)90021-B
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:S45-53; PMID:15812489; http://dx.doi.org/10.1038/nm1213
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58; PMID:16491139; http://dx.doi.org/10.1038/nri1777
   PubMed Web of Science ®Google Scholar
• Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984; 132:2736-41; PMID:6233359
   PubMed Web of Science ®Google Scholar
• Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59:301-8; PMID:3021614
   PubMed Web of Science ®Google Scholar
• Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988; 6:269-77; PMID:3048010; http://dx.doi.org/10.1016/0264-410X(88)90223-X
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896-903; PMID:14985487; http://dx.doi.org/10.1056/NEJMoa030595
   PubMed Web of Science ®Google Scholar
• Isaka M, Yasuda Y, Kozuka S, Taniguchi T, Matano K, Maeyama J, Komiya T, Ohkuma K, Goto N, Tochikubo K. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 1999; 18:743-51; PMID:10547435; http://dx.doi.org/10.1016/S0264-410X(99)00258-3
   PubMedGoogle Scholar
• Maeyama J, Isaka M, Yasuda Y, Matano K, Kozuka S, Taniguchi T, Ohkuma K, Tochikubo K, Goto N. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Microbiol Immunol 2001; 45:111-7; PMID:11293476; http://dx.doi.org/10.1111/j.1348-0421.2001.tb01276.x
   PubMedGoogle Scholar
• Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25:3752-62; PMID:17336431; http://dx.doi.org/10.1016/j.vaccine.2007.01.111
   PubMed Web of Science ®Google Scholar
• Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T, Sakurai K, Coban C, Horii T, Akira S, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010; 2:25ra24; PMID:20424013; http://dx.doi.org/10.1126/scitranslmed.3000759
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol 2011; 48:810-7; PMID:21257206; http://dx.doi.org/10.1016/j.molimm.2010.12.022
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72:955-62; PMID:6200641
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84; PMID:16763660; http://dx.doi.org/10.1038/nrd2059
   PubMed Web of Science ®Google Scholar
• Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31:2154-63; PMID:11449369; http://dx.doi.org/10.1002/1521-4141(200107)31:7%3c2154::AID-IMMU2154%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs. J Immunol 2001; 166:2372-7; PMID:11160295; http://dx.doi.org/10.4049/jimmunol.166.4.2372
   PubMed Web of Science ®Google Scholar
• Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000; 164:944-53; PMID:10623843; http://dx.doi.org/10.4049/jimmunol.164.2.944
   PubMed Web of Science ®Google Scholar
• Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, Jahrsdorfer B, Giese T, Endres S, Hartmann G. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004; 103:3058-64; PMID:15070685; http://dx.doi.org/10.1182/blood-2003-08-2972
   PubMed Web of Science ®Google Scholar
• Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 2010; 20:93-101; PMID:20384481; http://dx.doi.org/10.1089/oli.2009.0210
   PubMedGoogle Scholar
• Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992; 148:4072-6; PMID:1376349
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992; 36:983-97; PMID:1281260; http://dx.doi.org/10.1111/j.1348-0421.1992.tb02102.x
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999; 52:1-11; PMID:10808252
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 74(6522):546-9; PMID:7700380
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev 1994; 4:119-22; PMID:7950298
   PubMedGoogle Scholar
• Kuramoto E, Yano O, Kimura Y, Baba M, Makino T, Yamamoto S, Yamamoto T, Kataoka T, Tokunaga T. Oligonucleotide sequences required for natural killer cell activation. Jpn J Can Research 1992; 83:1128-31; PMID:1483927; http://dx.doi.org/10.1111/j.1349-7006.1992.tb02734.x
   PubMedGoogle Scholar
• Maeyama J, Takatsuka H, Suzuki F, Kubota A, Horiguchi S, Komiya T, Shimada I, Murata E, Osawa Y, Kitagawa H, et al. A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated TH1 immunity. PLoS One 2014; 9:e88846; PMID:24586411; http://dx.doi.org/10.1371/journal.pone.0088846
   PubMed Web of Science ®Google Scholar
• Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10:187-92; PMID:14745443; http://dx.doi.org/10.1038/nm987
   PubMed Web of Science ®Google Scholar
• Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172:1777-85; PMID:14734761; http://dx.doi.org/10.4049/jimmunol.172.3.1777
   PubMed Web of Science ®Google Scholar
• Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine 2012; 7:2181-95; PMID:22619554; http://dx.doi.org/10.2147/IJN.S30197
   PubMed Web of Science ®Google Scholar
• Maeyama JI, Komiya T, Takahashi M, Isaka M, Goto N, Yamamoto S. The mucosal adjuvanticity of the oligonucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid. Vaccine 2009; 27:1166-73; PMID:19136040; http://dx.doi.org/10.1016/j.vaccine.2008.12.025
   PubMedGoogle Scholar
• Osawa Y, Iho S, Takauji R, Takatsuka H, Yamamoto S, Takahashi T, Horiguchi S, Urasaki Y, Matsuki T, Fujieda S. Collaborative action of NF-kappaB and p38 MAPK is involved in CpG DNA-induced IFN-alpha and chemokine production in human plasmacytoid dendritic cells. J Immunol 2006; 177:4841-52; PMID:16982926; http://dx.doi.org/10.4049/jimmunol.177.7.4841
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Takii T, Yamamoto S, Maeyama J, Iho S, Maruyama M, Iizuka N, Ozeki Y, Matsumoto S, Hasegawa T, et al. Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCG. Immun Ageing 2013; 10:25; PMID:23799936; http://dx.doi.org/10.1186/1742-4933-10-25
   PubMedGoogle Scholar
• Maeyama JI. Mucosal adjuvants. BCG −Vaccine and Adjuvant−. In: Takii T, Maeyama JI, Yamamoto S, editors. Tokyo: JATA 2011. 177-92.
   Google Scholar